SHENZHEN, China, Sept. 8, 2021 /PRNewswire/ -- The other day Shenzhen Kangtai Biological Products Co., Ltd. announced that the company and AstraZeneca signed the "Amendment 1 to License Agreement". In ...

North America dominated the viral vector & plasmid DNA manufacturing market with a revenue share in 2024. Asia Pacific is expected to grow at the fastest CAGR in the market during the forecast period.

Demand for adeno-associated viral (AAV) vectors is increasing as more and more cell and gene therapy firms use them to make products. In response, vector suppliers are embracing faster, more efficient ...

The global viral vector manufacturing market is projected to expand at a robust CAGR of approximately 20% over the forecast period, supported by multiple transformative forces reshaping the ...

Vector Biolabs, a custom design and manufacturing service provider for AAV and adenovirus viral vectors announced the completion of a facility expansion to meet growing demand. The purpose of the ...

BOSTON & SEATTLE & COLUMBUS, Ohio--(BUSINESS WIRE)--GentiBio, Inc., an emerging biotherapeutics company developing best-in-class engineered regulatory T cells programmed to treat autoimmune, ...

Merck KGaA and subsidiary MilliporeSigma are doubling down on their gene therapy bets with a hefty nine-figure investment into expanded viral vector production. MilliporeSigma will spend $110 million ...

GERMANTOWN, MD AND CHICAGO, IL / ACCESS Newswire / December 16, 2025 / uBriGene Biosciences, a leading global lentivirus CDMO specializing in Advanced Therapy Medicinal Product (ATMP) GMP development ...